Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Onyx’s Cancer Drug’s Risk May Outweigh Benefit, FDA Says
Onyx’s Cancer Drug’s Risk May Outweigh Benefit, FDA Says
Onyx’s Cancer Drug’s Risk May Outweigh Benefit, FDA Says
Submitted by
admin
on June 18, 2012 - 11:04am
Source:
Bloomberg
News Tags:
FDA
Onyx
Kyprolis
Multiple Myeloma
Headline:
Onyx’s Cancer Drug’s Risk May Outweigh Benefit, FDA Says
Do Not Allow Advertisers to Use My Personal information
